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Abstract
Background: Molecular methods for the detection of drug-resistant tuberculosis are potentially more rapid than
conventional culture-based drug susceptibility testing, facilitating the commencement of appropriate treatment for patients
with drug resistant tuberculosis. We aimed to develop and evaluate high-resolution melting (HRM) assays for the detection
of mutations within gyrA, rpsL, and rrs, for the determination of fluoroquinolone and streptomycin resistance in
Mycobacterium tuberculosis (MTB).
Methodology/Principal Findings: A blinded series of DNA samples extracted from a total of 92 clinical isolates of MTB were
analyzed by HRM analysis, and the results were verified using DNA sequencing. The sensitivity and specificity of the HRM
assays in comparison with drug susceptibility testing were 74.1% and 100.0% for the detection of fluoroquinolone
resistance, and 87.5% and 100.0% for streptomycin resistance. Five isolates with low level resistance to ofloxacin had no
mutations detected in gyrA, possibly due to the action of efflux pumps, or false negativity due to mixed infections. One
fluoroquinolone-resistant isolate had a mutation in a region of gyrA not encompassed by our assay. Six streptomycin-
resistant strains had undetectable mutations by HRM and DNA sequencing, which may be explained by the fact that not all
streptomycin-resistant isolates have mutations within rpsL and rrs, and suggesting that other targets may be involved.
Conclusion: The HRM assays described here are potentially useful adjunct tests for the efficient determination of
fluoroquinolone and streptomycin resistance in MTB, and could facilitate the timely administration of appropriate treatment
for patients infected with drug-resistant TB.
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Introduction
Mycobacterium tuberculosis (MTB) is the world’s leading cause of
mortality due to an infectious agent with global estimates of 2 billion
people currently infected worldwide [1]. The WHO Report 2010
on ‘‘Global Tuberculosis Control’’ documents that in 2009 there
were 9.4 million incident cases of tuberculosis and approximately
1.3 million deaths (http://www.who.int/tb/publications/global_
report/2010/gtbr10_main.pdf). Complicating this scenario is the
emergence of multidrug-resistant tuberculosis (MDR-TB), defined
as resistance to two first-line antitubercular drugs, isoniazid and
rifampin, causing great global concern and resulting in an increased
need for the understanding of the molecular mechanisms and
molecular epidemiology of drug resistance [2,3,4]. In 2008, there
were an estimated 440,000 cases of MDR-TB, with the highest
numbers of cases occurring in China, India, the Russian Federation
and South Africa (http://www.who.int/tb/publications/global_
report/2010/gtbr10_main.pdf).
The current standard TB treatment regimen is in two stages:
two months of rifampin, isoniazid, pyrazinamide and ethambutol,
followed by four months of rifampin and isoniazid. MDR-TB
treatment requires use of second-line drugs such as fluoroquino-
lones (Moxifloxacin, gatifloxacin, levofloxacin) or injectable agents
such as aminoglycosides (streptomycin, amikacin, kanamycin) and
polypeptides (capreomycin) for typically two years [5,6]. These
second-line drugs are very poorly potent, highly toxic and
expensive. Thus, the rapid identification of drug-resistant MTB
using molecular methods could aid in more appropriate treatment
given earlier, and have the potential to decrease transmission of
the resistant strains. In addition, the development of a rapid, low
cost and sensitive assay could potentially be used in countries with
high rates of MTB and where cost effectiveness is essential.
Molecular methods for the determination of drug resistance are
designed to target specific genes known to harbor mutations
associated with resistance to specific anti-tuberculous drugs.
Mutations associated with fluoroquinolone resistance occur in
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the quinolone resistance-determining regions (QRDR) of the gyrA
and gyrB genes, which encode the A and B subunits of DNA
gyrase, with mutations at codons 90, 91 and 94 in gyrA being most
common [7,8,9,10]. Streptomycin resistance in MTB is associated
with mutations in rpsL and rrs, encoding the ribosomal protein S12
and 16S rRNA respectively [11,12]. Within the rpsL gene,
mutations at codons 43 and 88 have been reported in
streptomycin-resistant M. tuberculosis, with the K43R mutation
being the most common [12,13,14,15]. Mutations within rrs have
been found in the 530 loop, the 912 loop and the 1400 region, but
these are less common than mutations within the rpsL gene
[12,13,15].
The high-resolution melting (HRM) assay has been effectively
used to detect mutations within genes associated with human
diseases and in microbes, to subtype viruses, and for species
differentiation [16,17,18,19,20]. It has been widely utilized for a
variety of applications as it is cost-effective, rapid, sensitive, and
specific [21,22]. HRM employs saturating double-stranded DNA-
binding dyes included during the PCR process and the
denaturation of PCR amplicons with real-time monitoring of
fluorescence, following PCR. Sequence variants are detected from
differences in the melting profiles between test and reference
DNA. We have previously described a HRM assay for the
detection of resistance to the first-line antitubercular drugs,
isoniazid and rifampicin [22]. For this current study, we aimed
to develop a HRM assay to scan for mutations in gyrA, rpsL and rrs,
for the determination of fluoroquinolone and streptomycin
resistance in Mycobacterium tuberculosis.
Materials and Methods
Clinical isolates of Mycobacterium tuberculosis and drug
susceptibility testing
M. tuberculosis clinical isolates for assay development were
collected from the Central Tuberculosis laboratory, Department
of Pathology, Singapore General Hospital (SGH) and were
screened for drug susceptibility with the BACTEC 460 radiomet-
ric method (Becton Dickinson, Sparks, MD, USA), as described
previously [13,23,24].
For assay validation, a blinded series of 83 DNA samples of M.
tuberculosis were obtained from the Department of Microbiology, Li
Ka Shing Faculty of Medicine, the University of Hong Kong.
These isolates were tested for drug susceptibility as previously
described [25,26]. In addition, 9 blinded samples from SGH were
also used for validation. Of the total of 92 blinded samples, 53 and
62 were used for validation of our fluoroquinolone and
streptomycin HRM assays respectively.
DNA extraction
DNA was extracted from the M. tuberculosis clinical isolates from
Singapore as described previously [22,27]. DNA from clinical
isolates from Hong Kong was extracted as described [28], and
were further purified using phenol-chloroform-isoamyl alcohol
(25:24:1) (Invitrogen). DNA concentration was measured using the
Nanodrop 1000 (Thermo Scientific, Waltham, MA).
Real-time PCR and high-resolution melting analysis
Real-time PCR and high-resolution melting analysis was
performed as described previously [22]. In brief, PCR was
performed in 10-ul reactions containing 0.2 ng sample DNA,
0.2 ng reference DNA from Mycobacterium tuberculosis H37Rv, 16
PCR buffer containing 1.5 mM MgCl2, 200 mM dNTPs, 200 nM
of each primer (Table 1), 1.5 uM Syto9 (Invitrogen), 0.5 U of
HotStarTaq polymerase (Qiagen) and 4 ul of mineral oil (Sigma
Aldrich) on the Rotor-Gene 6000 (Corbett Research) with the
following PCR cycling parameters: 95uC for 15 minutes; 40 cycles
at 95uC for 20 seconds and the appropriate annealing temperature
(Table 1) for 30 seconds. The melt curve was generated by heating
at increments of 0.1uC/s, using the temperature ranges shown in
Table 1. The HRM curve was analyzed using the Rotor-Gene
1.7.87 software. (The Rotor-Gene is currently available from
Qiagen, which has acquired Corbett Research.)
DNA sequencing
Mutation screening by direct DNA sequencing was done as
described previously [13,23,26,29], or using the PCR primers
listed in Tables 1 or 2, with sequencing performed on an Applied
Biosystems 3130xl genetic analyzer.
Polymorphism detection for the gyrA HRM assay
A natural polymorphism occurs in codon 95 (Ser-95/Thr-95) of
gyrA [30,31]. In order to prevent false positive mutant detection in
susceptible isolates due to the presence of the gyrA codon 95
polymorphisms, two sets of gyrA HRM assays using reference DNA
with either the Ser-95 or Thr-95 polymorphism were done.
Genomic DNA from Mycobacterium tuberculosis strain H37Ra
(ATCC, USA) was used as the gyrA Ser-95 reference DNA, and
DNA from a previously sequenced fluoroquinolone-susceptible
strain was used as the gyrA Thr-95 reference. Samples with
mutations within gyrA will demonstrate changes in the melt curve
shape for both sets of reference DNA used, but polymorphisms at
codon 95 in susceptible isolates would be identified if deviations
are seen in only one set.
Sensitivity of the gyrA HRM assay in the detection of
mixed populations
Mixed populations of different M. tuberculosis strains have been
detected in clinical samples from pulmonary tuberculosis patients
[32,33]. To test the HRM assay for its limit in detecting mutations
within mixed populations, DNA of a gyrA mutant strain (D94G)
was titrated and mixed with DNA of a wildtype strain to artificially
create samples with mixed populations. The mutant DNA was
serially diluted at concentrations of 100%, 50%, 25%, 12.5% and
6.25%. Next, HRM was performed and the melting profiles were
compared with a 100% wildtype reference.
Statistical analysis
Sensitivity is defined as [Number of drug-resistant isolates with
mutations]/[number of drug-resistant isolates with mutations+
number of drug-resistant isolates without mutation]; and specific-
ity as [Number of drug-susceptible isolates without mutations]/
[number of drug susceptible isolates with mutations+number of
drug-susceptible isolates without mutations] [22]. Calculation of
the 95% confidence interval was performed using the Adjusted
Wald method (http://www.measuringusability.com/wald.htm).
Results
Representative normalized melt curves from HRM analysis of
gyrA, rpsL and rrs are shown in Figure 1. Samples with mutations,
represented by colored lines, are easily differentiated from the
susceptible (wildtype) isolates, indicated by black lines, by
differences in the shape of the melt curves. Note that there is
good concordance in the melting profile for the susceptible
isolates, with one composite melt curve for all the susceptible
isolates (including the reference DNA from MTB H37Rv), as
shown by the black line.
HRM Analysis of Drug-Resistant Tuberculosis
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Determination of fluoroquinolone resistance
A blinded series of 53 MTB clinical isolates were used for the
detection of fluoroquinolone resistance, by HRM analysis of the gyrA
gene. There were phenotypic and HRM genotypic concordance for
47 of 53 isolates (Table 3). The HRM assay was successful in
detecting previously reported gyrA mutations namely, H70R [34],
A74S [26], G88C, A90V, S91A, and D94A/G/H/Y
[35,36,37,38,39]. There were discrepant results for six isolates.
Five isolates had no mutations detected in gyrA by HRM analysis
and DNA sequencing, but were found to have low level resistance to
ofloxacin (MICs of 4 ug/ml) [25]. One other discrepant isolate had
a mutation (A126R) in gyrA outside the region encompassed by the
HRM assays (Table 1), identified by DNA sequencing. The HRM
results for mutation detection in gyrA were fully concordant with
DNA sequencing of the region encompassed by the HRM assay.
To specifically identify a polymorphism at codon 95 of gyrA, two
separate HRM experiments with either Ser-95 reference DNA or
Thr-95 reference DNA were performed. Figure 1A, using the Thr-
95 reference DNA showed no change in melting curve profile for a
non-mutant fluoroquinolone susceptible isolate with the S95T
polymorphism, however, the same isolate showed a deviation in
melt curve shape when Ser-95 reference DNA was used
(Figure 1B), thus clearly identifying this isolate as not being
mutated. In contrast, mutant samples had deviations in their melt
curve shapes for both sets of experiments (Figure 1A and 1B).
Determination of streptomycin resistance
HRM analysis of rpsL and rrs for the detection of streptomycin
resistance was performed on a blinded series of 62 M. tuberculosis
clinical isolates (Figure 1C–1F; Table 3). Phenotypic and HRM
genotypic determination of streptomycin susceptibility was con-
cordant for 56 of 62 isolates (Table 3). Six streptomycin-resistant
isolates did not have any detectable mutations using HRM analysis
of rpsL and rrs. Importantly, DNA sequencing of the regions
encompassed by the HRM assay showed concordance with the
HRM assay results for these isolates.
Table 1. Primer sequences used for fluoroquinolone and streptomycin resistance HRM detection assays.
Primer namea Primer sequence
Amplicon
size (bp)
Annealing
temp (6C)
HRM temp
range (6C)
Nucleotide
positionsb
HRM amplicon
rangec
Fluoroquinolone
gyrA_F 59-GGTGCTCTATGCAATGTTCG-39 211 60 92 to 95 162 to 181 Codon 61 to 118
gyrA_R 59-CGGTGGGTCATTGCCT-39 372 to 357
Streptomycin
rpsL_F 59-CAGCGTCGTGGTGTATGC-39 232 60 86 to 94 85 to 102 Codon 35 to 99
rpsL_R 59-CCTGCGTATCCAGCGAAC-39 316 to 299
rrs1_F 59-ACCGGCCAACTACGTGC-39 102 60 81 to 89 493 to 509 Nuclotide 510 to 575
rrs1_R 59-GAACAACGCGACAAACCAC-39 594 to 576
rrs2_F 59-CTAGGTGTGGGTTTCCTTCC-39 153 60 82 to 90 817 to 836 Nucleotide 837 to 943
rrs2_R 59-CGTTGCATCGAATTAATCCAC-39 964 to 944
rrs3_F 59-TCCCGGGCCTTGTACACA-39 62 60 80 to 87 1374 to 1391 Nucleotide 1392 to
1416
rrs3_R 59-CCACTGGCTTCGGGTGTTA-39 1435 to 1417
aF: Forward, R: Reverse.
bNucleotide position is relative to the transcriptional start site of each gene.
cAmplicon range of the HRM primers does not include the primer regions.
doi:10.1371/journal.pone.0031934.t001
Table 2. Primer sequences used to sequence rpsL, rrs, and gyrA.
Gene (Rv no.) Gene ID
Primer
name Lengtha Tm %GC
b Directionc Sequence (59- 39)
Nucleotide
position
gyrA (Rv0006) 887105 gyrA-F 20 59.3 50.0 F GGTGCTCTATGCAATGTTCG 162 to 181
gyrA-R 19 61.1 52.6 R GGGATATTGGTTGCCATGC 551 to 569
rpsL (Rv0682) 888259 rpsL-F 20 58.6 45 F AAAGCGCCCAAGATAGAAAG 227 to 27
rpsL-R 19 59.3 57.9 R CAACTGCGATCCGTAGACC 422 to 440
rrs (Rvnr01) 2700429 rrs1-F 20 57.3 45 F ATACCTTTGGCTCCCTTTTC 217 to 236
rrs1-R 21 59.6 57.1 R GGAAACCCACACCTAGTACCC 811 to 831
rrs2-F 20 59.8 55 F GCGCAGATATCAGGAGGAAC 688 to 707
rrs2-R 20 58.4 55 R CGCCCACTACAGACAAGAAC 1586 to 1605
aLength, number of nucleotides.
b%GC, number of G’s and C’s in the primer as a percentage of the total number of nucleotides.
cF, forward; R, reverse.
doi:10.1371/journal.pone.0031934.t002
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To determine if mutations not within the regions encom-
passed by the HRM assay may be present in the two isolates
with discrepant results, we sequenced rpsL and rrs in entirety.
Results from the sequencing showed a single rpsL mutation at
position 363 (ARG) which encodes for K121K, in both
samples. There was a single alteration (TRC) at position 15
in rrs in one sample, whereas the other sample had no
mutations in rrs.
Figure 1. Representative high resolution melt curves of (A) gyrA with Thr-95 control, (B) gyrA with Ser-95 control, (C) rpsL, and (D, E,
F) rrs fragments 1, 2, 3 respectively, demonstrating the change in melt curve shape caused by mutations. Wildtype samples are shown
in black and samples with mutations are shown in color. Experiments were performed in duplicate.
doi:10.1371/journal.pone.0031934.g001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31934
To determine if the rpsL K121K and the TRC alteration at
position 15 of rrs are present in other streptomycin-susceptible
isolates, 8 isolates were sequenced. All 8 streptomycin-susceptible
isolates had the rpsL K121K alteration but not the TRC alteration
at position 15 of rrs.
One isolate that was streptomycin-susceptible by phenotype,
had initially been found to be mutation-positive by HRM analysis,
but repeat testing on a re-extracted DNA sample showed no
mutations by HRM analysis. The initial discrepant result between
drug susceptibility and HRM testing may have been due to
contamination of the culture with a mutant strain, as subsequent
re-culture and re-extraction of that sample revealed no mutations.
Limit of detection of mutants in mixed populations
Titration of gyrA mutant (D94G) and wildtype DNA samples,
followed by HRM showed that mutations in samples are
detectable at a threshold limit of 25% (Figure 2).
Sensitivity and specificity
The sensitivity of the HRM assays for the detection of
fluoroquinolone and streptomycin resistance were 74.1% and
87.5% respectively, and the specificity values were 100.0% and
100.0% respectively (Table 4). The HRM assay was directly
compared to the conventional phenotypic assay to calculate the
sensitivity and specificity.
Discussion
Drug resistance in tuberculosis is currently determined using
culture-based methods such as the agar proportion method, or
liquid media methods like the BACTEC MGIT 960 which are
more rapid but which still require at least one week for the
determination of drug susceptibility [40,41]. In order to expedite
the determination of fluoroquinolone and streptomycin resistance
in MTB, we have developed HRM assays for the detection of
mutations in gyrA, rpsL and rrs, and have assessed the performance
of these assays using blinded series of DNA samples from drug-
resistant and –susceptible MTB clinical isolates.
There was a 100% concordance between the HRM assays and
DNA sequencing for all genes analyzed in this study. These HRM
assays are thus accurate, in addition to being easy to implement,
rapid and cost-effective [22]. The low cost of this assay, estimated
at US$0.30 per HRM reaction [22] would be an advantage in
countries where cost-effectiveness is important and where MTB
infection is prevalent, such as in India and China.
However, the disadvantage of using the HRM assay is that
multiple amplicons may have to be designed, especially for larger
Table 3. HRM results for the screening of fluoroquinolone and streptomycin resistance in blinded series of MTB samples.
Phenotype No. of isolates HRM and DNA sequencing resultsa
Fluoroquinolone gyrA
Susceptible (28) 28 NM
Resistant (25) 1 M [H70R (cAcRcGc)]
1 M [A74S (GccRTcc)]
1 M [G88C (GgcRTgc)]
1 M [A90V (gCtRgTg)]
1 M [A90V (gCtRgTg)]
1 M [S91A (TcgRCcg)]
1 M [D94Y (GacRTac)]
1 M [D94H (GacRCac)]
2 M [D94A (gAcRgCc)]
9 M [D94G (gAcRgGc)]
1b NM {A126R (GCgRAGg)}
5b NM
Streptomycin rpsL rrs
Susceptible (14) 14 NM NM
Resistant (48) 28 M [K43R (aAgRaGg)] NM
1 M [K43R (aAgRaGg)] M [nt.861 (ARG)]
1 M [K43R (aAgRaGg)] M [nt.1400 (ARG)]
1 M [K43R (aAgRaGg)] M [nt.513 (ARC)]
1 M [K43R (aAgRaGg)] M [nt.516 (CRT)]
5 N/A M [nt.513 (ARC)]
5 N/A M [nt.516 (CRT)]
1b NM {K121K (aaARaaG)} NM
1b NM {K121K (aaARaaG)} {nt.15 (TRC)}
4b NM NM
aHRM results are represented as ‘‘M’’ for mutant and ‘‘NM’’ for non-mutant. Mutations detected by DNA sequencing are represented in square brackets [ ], or by curly
brackets {} if the mutations are in regions not covered by the HRM assay.
bIsolates with discrepant HRM results as compared to their respective drug resistant phenotypes.
doi:10.1371/journal.pone.0031934.t003
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genes like rrs, since differences in melt curve shape are more easily
discriminated with smaller amplicons. In patients infected with
mixed bacterial populations [32,33], our gyrA assay has a limit of
detection of mutants of 25%, which may result in false negative
results for some patients. For genes such as gyrA, which has a
natural polymorphism within the region analyzed for HRM, two
sets of experiments need to be done, using reference DNA for both
alleles of the polymorphism. As mentioned in our previous
publication [26], the S95T polymorphism exists in all Beijing
strains, and hence in geographical regions where Beijing strains
are predominant, ofloxacin-susceptible clinical strains with the
S95T polymorphism should be selected as the reference for the
Figure 2. High resolution melt curves of a mutant DNA sample (gyrA D94G) serially diluted at concentrations of 100%, 50%, 25%,
12.5%, and 6.25%, and mixed with wildtype DNA. Wildtype samples are shown in black and samples with mutations are shown in color.
Changes in melt curve shape demonstrating the presence of mutations were observed in samples with 100%, 50% and 25% mutant DNA.
Experiments were performed in duplicate.
doi:10.1371/journal.pone.0031934.g002
Table 4. Sensitivity and specificity of the drug resistance detection HRM assays.
Drug susceptibility No. of isolates
Sensitivitya
(95% CIb)
Specificityc
(95% CIb)
Mutation positive by HRM Mutation negative by HRM
Fluoroquinolone (n =53) 19/25, 74.1% 28/28, 100.0%
Resistance 19 6 (56.3—88.8) (89.5—100.0)
Susceptible 0 28
Streptomycin (n =62) 42/48, 87.5% 14/14, 100.0%
Resistance 42 6 (74.9—94.5) (80.9—100.0)
Susceptible 0 14
a[Number of drug-resistant isolates with mutations]/[number of drug-resistant isolates with mutations+number of drug-resistant isolates without mutation].
bStatistical calculations were performed with the free software available from http://www.measuringusability.com/wald.htm using the Adjusted Wald method.
c[Number of drug-susceptible isolates without mutations]/[number of drug-susceptible isolates with mutations+number of drug-susceptible isolates without mutation].
doi:10.1371/journal.pone.0031934.t004
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first HRM assay. Only samples shown to have deviations in melt
curve shape in this first set of experiments need to be run in the
second set of experiments using Ser-95 (H37Ra) as reference.
Our HRM assay detected mutations within the gyrA gene in 19
of 25 (74.1%) fluoroquinolone-resistant isolates. Of the six resistant
isolates with no detectable mutations by HRM analysis, two
isolates had mutations in regions not encompassed by our assay,
while four isolates with low level resistance had no detectable
mutations within gyrA. It has been suggested that the mechanism
for resistance in such isolates may be mediated by active efflux
pumps, as in vitro studies have shown that the use of efflux pump
inhibitors resulted in the reduction of MIC levels [42,43,44].
The HRM assay for the detection of streptomycin-resistance
had a sensitivity and specificity of 87.5% and 100.0% respectively.
However, discrepant results between phenotyping and molecular
assays were obtained for two isolates which were streptomycin-
resistant by phenotype, but with no alterations detected by HRM.
DNA sequencing of the entire rpsL and rrs for these isolates
revealed alterations not within the region encompassed by the
HRM assay. The K121K alteration (AAARAAG) in rpsL, which
has previously been reported, was detected in both isolates
[29,45,46]. Niemann et al. (2009) has suggested the possibility of a
sequencing error in the original H37Rv sequence obtained from
PubMed (NCBI) resulting in this K121K ‘‘alteration’’ [47].
Sequencing of an additional eight streptomycin-susceptible isolates
revealed the K121K ‘‘alteration’’ in all samples, supporting
Niemann’s observation, and suggesting that it is a polymorphism.
In addition, DNA sequencing detected a T-to-C alteration at
position 15 in rrs in one sample that has not been previously
reported in streptomycin-resistant isolates, and which could
possibly be a novel mutation associated with resistance. This
finding warrants further investigation on additional streptomycin
resistant and susceptible isolates from other geographical locales.
Although mutations in rpsL and rrs are known to be associated
with streptomycin resistance, not all resistant isolates have
mutations in these genes. A higher frequency of mutations in rpsL
and rrs has been observed in geographical areas with a high
prevalence of Beijing strains, for example in Singapore, Latvia and
Japan [13,14,15]. However, in India, Rwanda and Yemen, none
to 20% of streptomycin resistant isolates had mutations in rpsL or
rrs [12,29]. This thus suggests that other additional genes may be
involved in streptomycin resistance, for instance the gidB gene that
encodes a 7-methylguanosine methytransferase specific for 16S
rRNA [48]. Although mutations in the gidB gene have been shown
to confer low-level streptomycin resistance, mutations in strepto-
mycin-susceptible clinical isolates have also been detected, and
thus further investigations are warranted to confirm the association
of gidB with streptomycin resistance [49,50].
The sensitivity of a molecular assay depends on the frequency of
detectable mutations within genes associated with resistance, in
resistant isolates. For example, mutations within the rifampicin
resistance-determining region (RRDR) of the rpoB gene, occur at
frequencies of .95% in rifampicin-resistant MTB isolates [51,52]
and thus molecular assays targeting rpoB would have a similarly
high sensitivity. In contrast, resistance associated mutations occur
at frequencies of 54.8 to 90% at the QRDR of gyrA in
fluoroquinolone-resistant isolates [53,54], and 0 to 95% in the
rpsL and rrs genes in streptomycin-resistant isolates [12,13,14,
15,29]. Not all resistant isolates have detectable mutations in genes
currently known to be associated with specific drug resistance and
therefore, in order to improve the sensitivity of molecular tests, it
will be necessary to discover additional novel genes associated with
resistance.
The HRM assays described here are potentially useful adjunct
tests for the rapid detection of fluoroquinolone and streptomycin
resistance in MTB, and could facilitate the timely administration
of appropriate treatment for patients with drug-resistant TB.
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